TruTag Technologies is looking to impact the food and drug industry with its edible security platform. “TruTags,” the company's microtags, can help to authenticate products without packaging or labels. DSN recently spoke with Kent Mansfield, president of TruTag Technologies.
Although the pace of approvals for new orphan drugs — medicines that treat relatively rare conditions — have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study released last week by the Tufts Center for the Study of Drug Development at Tufts University has concluded.
Asana BioSciences, a research and development company specializing in the discovery and development of new chemical and biological entities, on Tuesday announced that it has acquired an early stage branded pharmaceutical discovery platform from Endo Pharmaceuticals.
A drug maker has started a program to find the genetic determinants of human disease and speed the discovery and development of new drugs. The program includes a five-year project that it said would be one of the largest of its kind in terms of the number of patients involved.
An experimental drug therapy under development by Novartis for liver transplant patients appears to provide similar efficacy and better kidney function, compared with a drug made by Astellas Pharma, according to results of a late-stage clinical trial.
The number of new drug shortages has been halved as early notifications from manufacturers of potential shortages have increased sixfold, the commissioner of the Food and Drug Administration wrote Thursday.
A drug under investigation as a treatment for a rare genetic disorder that causes abnormally high triglyceride levels in the blood has received orphan-drug designation from the Food and Drug Administration.